Aura Biosciences, Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Aura Biosciences, Inc. (AURA) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax of -$290.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2026-08-11
- Aura Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-06-30 was -$290.00K.
- Aura Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2026-03-31 was -$78.00K.
- Aura Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-12-31 was -$11.00K.
- Aura Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2025-09-30 was $57.00K, a 92.78% decline year-over-year.
- Aura Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2025 was -$179.00K.
- Aura Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2024 was -$271.00K, a 144.35% decline from fiscal 2023.
- Aura Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2023 was $611.00K.
- Aura Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2022 was -$72.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$290.00K 10-Q · filed 2026-08-11 | -$368.00K 10-Q · filed 2026-08-11 | -$379.00K derived: sum of 3 quarters · filed 2026-08-11 | -$322.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$78.00K 10-Q · filed 2026-08-11 | -$89.00K derived: sum of 2 quarters · filed 2026-08-11 | -$32.00K derived: sum of 3 quarters · filed 2026-08-11 | -$120.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $46.00K derived: sum of 2 quarters · filed 2026-03-30 | -$42.00K derived: sum of 3 quarters · filed 2026-08-11 | -$179.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $57.00K 10-Q · filed 2025-11-13 | -$31.00K derived: sum of 2 quarters · filed 2026-08-11 | -$168.00K 10-Q · filed 2025-11-13 | -$507.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$88.00K 10-Q · filed 2026-08-11 | -$226.00K 10-Q · filed 2026-08-11 | -$564.00K derived: sum of 3 quarters · filed 2026-08-11 | $226.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$137.00K 10-Q · filed 2026-08-11 | -$476.00K derived: sum of 2 quarters · filed 2026-08-11 | $314.00K derived: sum of 3 quarters · filed 2026-08-11 | $113.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2024-12-31 | -$339.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $451.00K derived: sum of 2 quarters · filed 2026-03-30 | $250.00K derived: sum of 3 quarters · filed 2026-03-30 | -$271.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $790.00K 10-Q · filed 2025-11-13 | $589.00K derived: sum of 2 quarters · filed 2025-11-13 | $68.00K 10-Q · filed 2025-11-13 | $741.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$201.00K 10-Q · filed 2025-11-13 | -$722.00K 10-Q · filed 2025-08-13 | -$49.00K derived: sum of 3 quarters · filed 2025-11-13 | $40.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-03-31 | -$521.00K 10-Q · filed 2025-11-13 | $152.00K derived: sum of 2 quarters · filed 2025-11-13 | $241.00K derived: sum of 3 quarters · filed 2025-11-13 | $63.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2023-12-31 | $673.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $762.00K derived: sum of 2 quarters · filed 2025-03-24 | $584.00K derived: sum of 3 quarters · filed 2025-03-24 | $611.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $89.00K 10-Q · filed 2024-11-12 | -$89.00K derived: sum of 2 quarters · filed 2024-11-12 | -$62.00K 10-Q · filed 2024-11-12 | $13.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$178.00K 10-Q · filed 2024-11-12 | -$151.00K 10-Q · filed 2024-08-08 | -$76.00K derived: sum of 3 quarters · filed 2024-11-12 | -$95.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-03-31 | $27.00K 10-Q · filed 2024-11-12 | $102.00K derived: sum of 2 quarters · filed 2024-11-12 | $83.00K derived: sum of 3 quarters · filed 2024-11-12 | -$40.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2022-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $56.00K derived: sum of 2 quarters · filed 2024-03-27 | -$67.00K derived: sum of 3 quarters · filed 2024-03-27 | -$72.00K 10-K · filed 2024-03-27 |
| 2022-09-30 | -$19.00K 10-Q · filed 2023-11-09 | -$142.00K derived: sum of 2 quarters · filed 2023-11-09 | -$147.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$123.00K 10-Q · filed 2023-11-09 | -$128.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | -$5.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |